Crucell and Harvard (BIDMC) Join Forces with IAVI to Advance AdVac-based AIDS Vaccine

12-Aug-2010 - Crucell N.V. announces its intention to participate in an international Phase I clinical trial in the United States and Africa of a combination of two AdVac®-based AIDS vaccine candidates, Ad26.ENVA.01 and Ad35-ENV, in healthy adults who are not infected with HIV. The clinical trial, which will ...

Two new antibodies found to cripple HIV

HIV Findings reveal an Achilles heel on the virus for AIDS vaccine researchers to exploit

07-Sep-2009 - Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful new antibodies to HIV that reveal what may be an Achilles heel on ...

Zambia begins first preventive HIV vaccine trial

28-Apr-2006 - Targeted Genetics Corporation, the Zambia Emory HIV Research Project (ZEHRP) and the International AIDS Vaccine Initiative (IAVI) announced the initiation of a clinical trial in Zambia to test the safety and immunogenicity of tgAAC09, a preventive HIV vaccine. This is the first preventive HIV ...

HIV/AIDS Vaccine Trial in Entebbe, Uganda

Cooperation between the Uganda Virus Research Institute (UVRI), the International AIDS Vaccine Initiative (IAVI) and Targeted Genetics

08-Feb-2006 - Targeted Genetics Corporation, The Uganda Virus Research Institute (UVRI), and the International AIDS Vaccine Initiative (IAVI) announced the start of a Phase II clinical trial in Uganda to evaluate the safety and immunogenicity of tgAAC09, a preventive HIV/AIDS vaccine. This is the second ...